Imatinib, the magic bullet for treatment of blood cancer

Maria Teresa Esposito

Research output: Contribution to journalArticlepeer-review


Some say it's a magic bullet. Others refer to it as a miracle. Imatinib is a drug for a type of blood cancer.
Today patients who take Imatinib survive an average of 30 years. This means that most of them can live as long as any other person. This is amazing! In the 1980s a cancer patient could expect to live only three to five years. Imagine how devastating this was for the patient and the family!
But how did we get to Imatinib? Why is imatinib considered a miracle drug? And why is the story behind this drug so special? To answer these questions, we have to time travel to the past.
This article describes the astonishing discovery of Imatinib, the magic bullet for treatment of blood cancer, the resilience of the scientists behind this discovery and what we have learned from the development of this drug.
Original languageEnglish
JournalFrontiers for young minds
Publication statusPublished - 26 Feb 2020

Cite this